Quintrio
Home

Stock overview

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Last trade $49.33
Day change -$1.085 (-2.15%)
Day range $49.27 – $50.50
Volume 1,886,346
Market cap $101.05B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for GSK.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for GSK.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

Zacks Investment Research

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.

The Motley Fool

GSK: 3 Key Takeaways for Long-Term Investors

GSK reported Q3 2026 earnings with 5% sales growth to GBP 8.9 billion, reconfirming full-year guidance. The company is accelerating its R&D pipeline with 18 phase 3 clinical trials started in 2026 and expects 22 by year-end. Specialty medicines, particularly long-acting HIV treatments like Cabenuva, drove 15% growth and higher margins. Management's Accelerate Growth restructuring program redirects cost savings toward late-stage drug development while maintaining operating profit margins, positioning the company for sustained long-term value creation.

GlobeNewswire Inc.

Ziphius, une société de biotechnologie de premier plan spécialisée dans l’ARN auto-amplificateur, annonce aujourd’hui la nomination de M. Antoon Loomans au sein de son conseil d’administration

Ziphius, a biotechnology company specializing in self-amplifying RNA (saRNA), announced the appointment of Antoon Loomans to its Board of Directors. Loomans, a veteran vaccine industry executive with 30 years of experience including 27 years at GSK and recent role at VaxCo (acquired by Eli Lilly for $1.55B), will lead commercial development in the US focusing on strategic partnerships and licensing. The appointment comes as Ziphius advances its lead Chlamydia trachomatis vaccine candidate toward clinical trials and conducts a €30 million fundraising round.

GlobeNewswire Inc.

Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsight

The systemic sclerosis market is valued at USD 1.9 billion in 2025 and is projected to grow at a 3% CAGR through 2036. Growth is driven by increasing disease awareness, diagnostic advancements, and an expanding pipeline of emerging therapies including anifrolumab, belimumab, efzofitimod, and nemolizumab. The U.S. accounts for 55% of the market, with approximately 232K diagnosed cases across the 7MM in 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 13, 2026$0.4518Jan 7, 2027recurring
Aug 14, 2026$0.4501Oct 8, 2026recurring
May 15, 2026$0.455Jul 9, 2026recurring
Feb 20, 2026$0.4776Apr 9, 2026recurring
Nov 14, 2025$0.4331Jan 8, 2026recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 19, 20224-for-5reverse split